ClinicalTrials.gg
CompletedNCT03739710Updated Jun 15, 2025Results posted

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Docetaxel and Feladilimab in Neoplasms, sponsored by GlaxoSmithKline. Completed at 57 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
38th of 188
175 · median 50
Started
2019
with 2 others
Phase 2
125 of 198
9 open now
Registered
173rd of 198
by date

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 38th largest by enrollment of the 188 interventional ones that give a count, is one of 3 that started in 2019, is one of 125 in phase 2, and was the 173rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A (belrestotug) and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448/belrestotug.

03

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Non-small cell lung cancer
  • Inducible t-cell co-stimulator (ICOS)
  • Docetaxel
  • Standard of care
  • Immuno-oncology agents
  • TIGIT
  • Dostarlimab
  • Jemperli
  • GSK4428859A
  • belrestotug
  • EOS884448
  • GSK6097608
  • Anti-TIGIT
  • CD-96
  • Anti-CD-96
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 175 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants capable of giving signed /assent.
  • Male or female, aged 18 years or older at the time consent is obtained. Participants in Korea must be age 19 years or older at the time consent is obtained.
  • Participants with or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and

    a) Documented disease progression based on radiographic imaging, during or after a maximum of 2 for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD[L]1) monoclonal antibody (mAb) containing regimen.

    b) Participants with known BRAF molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.

    c) Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria

  • , presenting with at least 1 measurable lesion per RECIST 1.1.
  • (ECOG) Performance Status (PS) score of 0 or 1.
  • A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, is acceptable.
  • Adequate organ function as defined in the protocol.
  • A male participant must agree to use a highly effective during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:

    i) Not a woman of (WOCBP) or ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.

  • of at least 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):

    1. Docetaxel at any time.
    2. Any of the agents being tested in the current study.
    3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.
    4. Prior radiation therapy: permissible if at least one non-irradiated is available for assessment per version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.
  • Received greater than (>)2 for NSCLC, including participants with BRAF molecular alternations.
  • Invasive or history of invasive malignancy other than disease under study within the last 2 years, except

    • Any other invasive malignancy for which the participant was definitively treated, has been disease-free for at least 2 years and in the opinion of the principal investigator and GlaxoSmithKline Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial.
    • Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma.
  • Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) .
  • Major surgery less than or equal to (\<=) 28 days of first dose of study treatment.
  • disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.
  • Receiving systemic steroids (>10 milligrams [mg]) oral prednisone or equivalent) or other agents within 7 days prior to first dose of study treatment.
  • Prior allogeneic/autologous bone marrow or solid organ transplantation.
  • Receipt of any within 30 days prior to first dose of study treatment.
  • Toxicity from previous anticancer treatment that includes:

    1. Greater than or equal to (>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.
    2. History of myocarditis of any grade during a previous treatment with immunotherapy
    3. Toxicity related to prior treatment that has not resolved to \<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \<= Grade 2).
  • History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past- pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.
  • Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.
  • Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.
  • History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include

    1. Serious, uncontrolled cardiac arrhythmia or abnormalities including second degree (Type II) or third degree atrioventricular block.
    2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.
    3. Symptomatic pericarditis.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Active infection requiring systemic therapy \<=7 days prior to first dose of study treatment.
  • Participants with known infection.
  • Participants with history of severe to mAb or hypersensitivity to any of the study treatment(s) or their .
  • Participants requiring ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome P 3A4 () enzymes.
  • Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining , or compliance to the study procedures in the opinion of the investigator.
  • Pregnant or lactating female participants.
  • Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.
  • Participants with presence of surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.
  • Receipt of transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Part 1: Participants receiving feladilimab and ipilimumab

    Drug: Feladilimab · Drug: Ipilimumab

  • Experimental
    Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448/belrestotug

    Drug: GSK4428859A · Drug: Dostarlimab

  • Experimental
    Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448/belrestotug plus GSK6097608

    Drug: GSK4428859A · Drug: Dostarlimab · Drug: GSK6097608

  • Active comparator
    Part 2: Participants receiving SoC: docetaxel

    Drug: Docetaxel

  • Experimental
    Part 2: Participants receiving feladilimab and docetaxel

    Drug: Docetaxel · Drug: Feladilimab

Interventions

  • Docetaxel will be administered.

  • Feladilimab will be administered.

  • Ipilimumab will be administered.

  • GSK4428859A/EOS884448 will be administered.

    Also known as: belrestotug, EOS884448

  • Dostarlimab will be administered.

  • GSK6097608 will be administered.

07

What researchers measure

Primary outcomes

  1. Number of Participants Randomized Across Sub-studies

    Number of Participants randomized across sub studies are presented.

    Time frame: Day 1

08

Results

Posted Jun 15, 2025

Participant flow

This master record includes data of screened participants for its sub-studies, 205801-001 (NCT05553808), 205801-002 (NCT06790303) and 205801-003 (NCT06926673) and only contains data during screening phase (Day -28 to Day 0). Results are presented separately for each sub study.

Participant flow — Overall Study
MilestoneAll Screened Participants
Started256
Completed175
Not completed81
Withdrew: Screen failed81

Outcome measures

PrimaryNumber of Participants Randomized Across Sub-studies

Number of Participants randomized across sub studies are presented.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants Randomized Across Sub-studies
ParticipantsAll Screened Participants
Sub Study 1105
Sub Study 28
Sub Study 362

Adverse events

Collected over Screening (-28 to 0 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Screened Participants0/256 (0%)0/256 (0%)0/256 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)All Screened Participants
18-64 years127
Over 64 years129
Sex: Female, Male
Sex: Female, Male(Participants)All Screened Participants
Female86
Male170
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Screened Participants
White216
Unknown or Not Reported12
All other races28
09

Study locations

57 sites
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110-1093, United States
  • GSK Investigational Site
    Bronx, New York 10461-2375, United States
  • GSK Investigational Site
    Pinehurst, North Carolina 28374, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Brampton, Ontario L6R 3J7, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Caen Cedex 9, 14033, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Paris, 75248, France
  • GSK Investigational Site
    Saint-Herblain, 44093, France
  • GSK Investigational Site
    Villejuif Cedex, 94805, France
  • GSK Investigational Site
    Berlin, 14165, Germany
  • GSK Investigational Site
    Gauting, 82131, Germany
  • GSK Investigational Site
    Grosshansdorf, 22927, Germany
  • GSK Investigational Site
    Heidelberg, 69126, Germany
  • GSK Investigational Site
    Immenhausen, 34376, Germany
  • GSK Investigational Site
    Kassel, 34125, Germany
  • GSK Investigational Site
    Leipzig, 04357, Germany
  • GSK Investigational Site
    Meldola FC, 47014, Italy
  • GSK Investigational Site
    Milano, 20133, Italy
  • GSK Investigational Site
    Napoli, 80131, Italy
  • GSK Investigational Site
    Orbassano TO, 10043, Italy
  • GSK Investigational Site
    Ravenna, 48121, Italy
  • GSK Investigational Site
    Siena, 53100, Italy
  • GSK Investigational Site
    Cheongju Chungcheongbuk-do, 28644, Korea, Republic of
  • GSK Investigational Site
    Gyeonggi-do, 10408, Korea, Republic of
  • GSK Investigational Site
    Seongnam-si Gyeonggi-do, 13620, Korea, Republic of
  • GSK Investigational Site
    Seoul, 05505, Korea, Republic of
  • GSK Investigational Site
    Amsterdam, 1081 HV, Netherlands
  • GSK Investigational Site
    Maastricht, 6229 HX, Netherlands
  • GSK Investigational Site
    Lodz, 93-513, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Warszawa, 02-781, Poland
  • GSK Investigational Site
    Bucharest, 020142, Romania
  • GSK Investigational Site
    Craiova, 200347, Romania
  • GSK Investigational Site
    Floresti, 407280, Romania
  • GSK Investigational Site
    Otopeni, 075100, Romania
  • GSK Investigational Site
    Timisoara, 300166, Romania
  • GSK Investigational Site
    Chelyabinsk, 454048, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 197183, Russian Federation
  • GSK Investigational Site
    St-Petersburg, 194291, Russian Federation
  • GSK Investigational Site
    Badajoz, 06080, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28027, Spain
  • GSK Investigational Site
    Madrid, 28033, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Malaga, 29010, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Sevilla, 41009, Spain
  • GSK Investigational Site
    Stockholm, SE-171 64, Sweden
  • GSK Investigational Site
    Uppsala, SE- 75 185, Sweden
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in May 2024, 63 months.

Results were first posted in Jun 2025, 1 year 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 63 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 14, 2018
StartActual
Jan 24, 2019
Primary completionActual
May 2, 2024
CompletionActual
May 2, 2024
Results first posted
Jun 15, 2025
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03739710
Lead sponsor
GlaxoSmithKline
Collaborators
iTeos Belgium SA
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Jan 24, 2019
Primary completion
May 2, 2024
Completion
May 2, 2024
Results posted
Jun 15, 2025
Last update
Jun 15, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Feladilimab · Belrestotug · Nelistotug

Start the discussion